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Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder characterized by the selective death of motor neurons in the
motor cortex, brainstem, and spinal cord. A large number of rodent models are available that show motor neuron death and a
progressive motor phenotype that is more or less reminiscent of what occurs in patients. These rodent models contain genes with
spontaneous or induced mutations or (over) express diﬀerent (mutant) genes. Some of these models have been of great value to
delineate potential pathogenic mechanisms that cause and/or modulate selective motor neuron degeneration. In addition, these
genetic rodent models play a crucial role in testing and selecting potential therapeutics that can be used to treat ALS and/or other
motorneurondisorders.Inthispaper,wegiveasystematicoverviewofthemostimportantgeneticrodentmodelsthatshowmotor
neuron degeneration and/or develop a motor phenotype. In addition, we discuss the value and limitations of the diﬀerent models
and conclude that it remains a challenge to ﬁnd more and better rodent models based on mutations in new genes causing ALS.
1.Introduction
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative
disease characterized by the selective death of motor neurons
in the motor cortex, brainstem, and spinal cord. Typically,
ALS is an adult-onset disorder with a fast progression. About
5% to 10% of ALS patients have a family history (FALS), and
most of these patients inherit the disease in an autosomal
dominant way. The large majority of patients (90% to 95%)
have no clear family history and are considered as sporadic
ALS (SALS). FALS and SALS are clinically indistinguishable,
and all patients experience muscle weakness, atrophy, and
spasticity. This is the consequence of the loss of both
upperandlowermotorneurons.Ultimately,patientsbecome
paralyzed and denervation of respiratory muscles causes the
death of the patient, on average three to ﬁve years after the
ﬁrst clinical signs. As studying a sporadic disease is very
diﬃcult,mostresearchfocusedonthegeneticcausesofFALS
(for reviews see [1–3]).
The most important and most studied cause of FALS
are mutations in the gene encoding superoxide dismutase 1
(SOD1). On average, SOD1 mutations are responsible for
about 20% of FALS cases [4]. Recently, mutations in the
genes encoding the TAR DNA-binding protein 43 (TDP-43;
[5–9]) and FUS/TLS [10, 11] were identiﬁed as important
gene defects causing typical FALS in approximately 5%–10%
of the familial cases.
All other genetic causes of FALS are rare and/or cause
an atypical form of ALS. These include mutations in the
genes encoding alsin (ALS2; [12]), senataxin (ALS4; [13]),
spatacsin (ALS5; [14]), vesicle-associated membrane protein
B( V A P B ;A L S 8 ;[ 15]), angiogenin (ALS9; [16]), optineurin
(ALS12; [17]), and dynactin [18]. In addition, (rare)
sequence variants in a number of other genes were reported
to be associated with ALS. These variations were found in
candidate genes or through genome wide association studies
[2]. In all cases, it is unclear whether these genes and/or
variations play a role in ALS, and these associations remain
to be conﬁrmed.
For years, a number of mouse models exist that contain
spontaneous or induced mutations leading to motor neuron
death (Table 1). More recently, the mutated genes that lead
to this phenotype were discovered. In addition and in an
attempt to unravel the pathogenic mechanism(s) leading to
ALS, a number of rodent models have been created starting
from information on the genetic causes of ALS (Tables 2
and 3). Moreover, some transgenic animals show motor
neuron degeneration as a prominent and unexpected feature2 Journal of Biomedicine and Biotechnology
while the (over)expressed genes do not cause ALS (Table 3).
In this paper, we will give a systematic overview of the
most important rodent models that show motor neuron
degeneration and discuss the value and limitations.
2.Spontaneousor InducedMotor Neuron
DegenerationinMice
2.1. Wobbler Mouse. The Wobbler mouse arose as the result
of a spontaneous mutation at the “Institute of Animal
Genetics” in Edinburgh. These mice have an unsteady
gait with progressive weakness. The most characteristic
abnormalityfoundintheWobblermouseisthedegeneration
of nerve cells of the motor system in the brainstem and in the
spinalcord.Thisresultsinprogressivedenervationofskeletal
muscles, leading to muscle atrophy especially in the head,
neck, and forelimbs while the hind limbs are less severely
aﬀected [19]. The course of the disease varies in diﬀerent
mice and is also dependent on the genetic background [19,
24, 25]. Usually after a period of rapid deterioration up to
the third or fourth month of age, the progress of the disease
slows down. Some aﬀe c t e dm i c el i v ef o rm o r et h a nay e a r
in spite of muscle weakness and wasting. In other cases, the
disease causes a more extensive and severe muscle weakness
and is fatal by the third or fourth month [19].
Originally, the Wobbler mouse was considered as a good
model of motor neuron degeneration. However, this mouse
model does not develop a typical motor neuron disease. The
degeneration of motor neurons and the onset of astrogliosis
and microgliosis in the spinal cord seem to be preceded by
a more widespread neurodegeneration [26]. In addition, the
Wobbler mice also show impaired spermiogenesis [27].
The gene mutated in this autosomal recessive disease
model is VPS54 encoding a subunit of the Golgi-associated
retrograde protein (GARP) complex that is required for
tethering and fusion of endosome-derived transport vesicles
to the trans-Golgi network, and the mutation leads to an
amino acid replacement (Q967L) in the C-terminal domain
of the Vps54 protein [28]( Table 1).
2.2. Nmd Mouse Model. The “Neuromuscular degeneration”
(Nmd) mouse contains a spontaneous autosomal recessive
mutation that leads to neuromuscular degeneration [20].
These mice develop a progressive motor neuron disease in
which motor neuron loss causes muscle atrophy. Homozy-
gous Nmd mice become progressively paralyzed and rarely
survive longer than 4 weeks after birth.
A mutation that creates a cryptic donor splice site was
found in intron 4 of the gene encoding the immunoglobulin
μ-binding protein 2 (IGHMBP2) [47], that colocalizes with
the RNA-processing machinery. The consequence of this
mutation is that the majority of the Ighmbp2 transcripts are
aberrantly spliced and that a truncated Ighmbp2 protein is
formed. This mouse model became highly relevant after the
discovery of Ighmbp2 mutations in patients suﬀering from
spinal muscular atrophy with respiratory distress (SMARD)
type 1 [48]. SMARD is an autosomal recessive motor neuron
disease that aﬀects infants. Patients present with respiratory
distress due to diaphragmatic paralysis and progressive
muscle weakness with predominant distal lower limb muscle
involvement (Table 1).
2.3. Pmn Mouse. The “Progressive motor neuronopathy”
(Pmn) mutant mouse develops hindlimb paralysis and
displays progressive degeneration of motor axons while the
cell bodies of the motor neurons in the ventral spinal cord
are unaﬀected [21]. The Pmn mice die in the early postnatal
period (6-7 weeks) [21]. The pathology in the Pmn mouse
is considered as a distal axonopathy, and as a consequence
the Pmn mouse may represent a good animal model of
hereditary motor neuropathies.
The underlying genetic cause of the disease in the Pmn
mouseisapointmutationintheTBCE geneonchromosome
13[49].Thegeneproductisthetubulin-speciﬁcchaperoneE
(Tbce) that has an eﬀect on microtubule stability and/or on
the polymerization dynamics of microtubules. In humans,
a deletion in Tbce is responsible for hypoparathyroidism-
retardation dysmorphism syndrome (HRD or Sanjad-Sakati
syndrome, SSS) or autosomal recessive Kenny-Caﬀey syn-
drome (AR-KCS). Although neurological signs are part of
the HRD/SSS phenotype, this syndrome is clinically variable,
involves multiple tissues, and is quite diﬀerent from the
disease observed in the Pmn mouse (Table 1).
2.4. Loa and Cra Mice. Two independent N-ethyl-N-
nitrosourea-(ENU) induced mutagenesis experiments gen-
erated the mutant mouse lines: “Legs at odd angles” (Loa)
[22] and “Cramping 1” (Cra) [23]. These mice manifest pro-
gressive motor neuron disorders and show remarkable sim-
ilarities to speciﬁc features of human pathology, including
Lewy body-like inclusions containing SOD1, neuroﬁlaments
(NFs), and ubiquitin.
Two diﬀerent point mutations in the gene encoding
dynein were found in the Loa and Cra mice [68]. In the Loa
mouse a mutation is present that changes phenylalanine to
tyrosine at position 580 (F580Y), while the Cra mutation
converts tyrosine 1055 to a cysteine (Y1055C). Dynein is a
motor protein that is involved in retrograde transport and
moves in the minus-end direction along microtubules. The
genetic cause and phenotype of the Loa and Cra mouse
models were often used as an argument in favor of the
hypothesis that disturbances in axonal transport lead to
selective motor neuron loss.
However, the validity of the Loa mouse as a model for
ALS was questioned by the observation that no selective loss
of motor neurons was detected [69]. In contrast, postnatal
loss of lumbar proprioceptive sensory axons, accompanied
by decreased excitatory glutamatergic input to motor neu-
rons, was observed [69]. It was suggested that this reduction
in glutamatergic input from lost proprioceptive sensory
axonsistheunderlyingcauseoftheunexpectedprolongation
of the life span of one of the mutant SOD1 mouse models
(see below) after crossbreeding with the Loa mice [70]. This
ﬁts with the idea that excitotoxicity plays an important role
in the selective motor neuron death underlying ALS [71].
Also the Cra mice do not show motor neuron loss,
not even in aged animals [72]. In contrast, Cra miceJournal of Biomedicine and Biotechnology 3
Table 1: Overview of spontaneous or induced mouse models showing motor neuron degeneration.
Name Mutated gene Gene product Inheritance Human disease Reference
Wobbler VPS54 Subunit of the GARP complex recessive NA [19]
Nmd IGHMBP2 Immunoglobulin μ-binding protein 2 recessive SMARD1 [20]
Pmn TBCE tubulin-speciﬁc chaperone E recessive motor neuropathy HRD/SSS [21]
Loa DYNC1H1 dynactin dominant sensory neuropathy [22]
Cra DYNC1H1 dynactin dominant sensory neuropathy [23]
SMARD: spinal muscular atrophy with respiratory distress, HRD: hypoparathyroidism-retardation dysmorphism syndrome, SSS: Sanjad-Sakati syndrome,
and NA: not available.
Table 2: Overview of transgenic rodent models for motor neuron degeneration (Mendelian and typical FALS).
Disease Gene product Inheritance Animal Genetic modiﬁcation Reference
ALS1 Superoxide dismutase 1 Dominant Mouse genomic hSOD1 G37R [29]
genomic hSOD1 G85R [30]
genomic mSOD1 G86R [31]
genomic hSOD1 G93A [32]
genomic hSOD1 L126Z(stop) [33]
genomic hSOD1 L126delTT [34]
genomic hSOD1 Quad [35]
PrP; cDNA SOD1 G37R [35]
Thy-1; cDNA hSOD1 G93A [36]
Rat genomic hSOD1 H46R [37]
genomic hSOD1 G93A [37]
genomic hSOD1 G93A [38]
Dominant/recessive Mouse genomic hSOD1 D90A [39]
ALS6 FUS/TLS Dominant (recessive) Mouse FUS/TLS KO [40, 41]
ALS10 TDP-43 Dominant Mouse Prp; hTDP-43 A315T [42]
Thy-1; hTDP-43 WT [43]
PrP; hTDP-43 WT [44]
PrP; hTDP-43 A315T [44]
PrP; hTDP-43 M337V [44]
PrP; hTDP-43 WT [45]
Rat TRE; hTDP-43 M337V and WT [46]
hSOD1: human superoxide dismutase 1, mSOD1: mouse superoxide dismutase 1, FUS: fused in sarcoma, TLS: translocated in liposarcoma, KO: knockout,
PrP: prion promoter, TRE: tTA-activated promoter.
show a prominent degeneration of sensory neurons. As a
consequence, it was suggested that the Cra mice should be
considered as a model for sensory neuropathies rather than
for motor neuron disease (Table 1). In addition, a recent
study showed that the Cra mice also loose striatal neurons
supporting a role for dynein dysfunction in the pathogenesis
of neurodegenerative disorders of the basal ganglia such as
Perry syndrome and Huntington’s disease [73].
3. Rodent Models of Typical MendelianFALS
3.1. ALS1: Superoxide Dismutase 1; 21q
3.1.1. Transgenic Mice. After the discovery of mutations in
the SOD1 gene, a transgenic mouse overexpressing mutant
(G93A) SOD1 was created by insertion of multiple copies
of human genomic SOD1 into the mouse genome [32].
These transgenic mice show progressive hind limb weakness
leading to paralysis and death and replicate in an almost
perfect way the disease process in patients. The moment
of disease onset and the life span of these mice are related
to the level of overexpression of mutant SOD1, while
overexpression of nonmutated SOD1 gives no phenotype.
In addition to the original mutant (G93A) SOD1 mice,
a large number of other transgenic mice that (over)express
human SOD1 containing other mutations (G37R, G85R
or D90A) or mutant (G86R) mouse SOD1 were created
(Table 2), and these mice show a similar phenotype as
the mutant (G93A) SOD1 mouse line [29–31, 39]. Also
transgenic mice overexpressing an SOD1 that was truncated
at the C-terminus show clear motor neuron degeneration
[33, 34].
The diﬀerent mutant SOD1 mouse models have been
extensively studied and strongly indicate that mutant SOD1
causes selective motor neuron death by a “gain of function”
Moreover, these mice were used to study the pathogenic4 Journal of Biomedicine and Biotechnology
Table 3: Overview of transgenic mouse models for motor neuron degeneration (atypical or rare FALS and candidate genes).
Disease Gene product Inheritance Animal Genetic modiﬁcation Reference
ALS2 Alsin Recessive Mouse KO (exon 3) [50]
KO (stop codon in exon 3) [51]
KO (exon 3 and 4) [52]
KO (exon 4) [53]
ALS8 VAPB Dominant Mouse PrP; VAPB P56S [54]
ALS Dynactin Dominant Mouse Knock-in G59S p150Glued [55]
Thy-1; G59 p150Glued [56, 57]
CMT2E/1F Neuroﬁlament-L Dominant Mouse NF-L L394P [58]
NA Peripherin NA Mouse overexpression [59]
NA Vascular endothelial growth factor NA Mouse VEGFδ/δ [60]
FTDP-tau tau Dominant Mouse 4R human tau [61]
R406W human tau [62, 63]
P301L human tau [64]
G272V, P301S human tau [65]
V337M human tau [66]
P301S human tau [67]
PrP: prion promoter, CMT: Charcot-Marie-Tooth, FTDP: frontotemporal dementia with parkinsonism, and NA: not available.
changes occurring during the disease process, and they were
alsocrossbredwithmanyothertransgenicmicetogetinsight
about the pathogenic mechanism(s) involved. From one of
these crossbreedings, it was concluded that mutant SOD1-
mediated oxidative abnormalities are not the primary cause
of mutant SOD1 toxicity. SOD1 is an enzyme that requires
copper to catalyze the conversion of toxic superoxide radicals
into hydrogen peroxide and oxygen. Copper plays a crucial
role in the normal and/or aberrant enzymatic activity of
the enzyme, and copper loading of SOD1 is performed
by a speciﬁc copper chaperone (CCS). Crossbreeding of
transgenic mutant (G93A) SOD1 mice with knockout mice
lacking the CCS, does not inﬂuence the life span of mutant
(G93A) SOD1 mice [74]. Another argument that oxidative
stress induced by mutant SOD1 is not the initiating factor
is provided by the transgenic mice overexpressing mutant
SOD1 in which the histidines that bind copper are mutated
(SOD1-Quad). Two of these mutations are known human
mutationsthatcauseALS,andtheSOD1-Quadmicedevelop
age-dependent motor neuron loss despite the lack of copper
binding by SOD1 [35].
The mutant SOD1 models were also used to clarify the
contribution of diﬀerent cell types in the disease process.
Selective (over)expression of mutant SOD1 in motor neu-
rons [75]o ri ng l i a lc e l l s[ 76]i sn o ts u ﬃcient to induce
a motor phenotype, indicating that an interplay between
diﬀerent cell types is needed to get motor neuron death.
However,itisunclearwhethermutantSOD1isexpressedtoa
suﬃciently high level in these transgenic mice. Other studies
reported that exclusive neuronal expression of mutant SOD1
can cause motor neuron degeneration [36, 77] and can also
lead to paralysis [36]. The involvement of nonneuronal cell
types in mutant SOD1-induced motor neuron death was
proven by using a transgenic mouse that contains a ﬂoxed
mutant (G37R) SOD1 gene. This gene can be excised in
diﬀerentcelltypesbytheactionofCrerecombinase.Selective
reduction of the amount of mutant SOD1 in microglia and
peripheral macrophages has a dramatic eﬀect and delays
signiﬁcantly the progression of the disease [78]. Moreover,
reduction of mutant SOD1 expression in astrocytes also
aﬀects disease progression. This selective silencing of mutant
SOD1 expression in astrocytes is obtained by crossbreeding
transgenic mice containing ﬂoxed mutant SOD1 with mice
expressing Cre driven by the glial ﬁbrillary acidic protein
(GFAP) promoter [79]. In the mutant (G37R) SOD1, the
disease progression is signiﬁcantly slowed, and the eﬀect on
survival is comparable to that of the selective removal of
mutant (G37R) SOD1 from postnatal motor neurons [78,
79]. In mutant (G85R) SOD1 mice, the onset as well as the
earlydiseasephaseisaﬀectedindicatingthatdiﬀerentmutant
SOD1s may have diﬀerent characteristics [80]. Altogether,
these data show that the expression of mutant SOD1 in
astrocytes and microglial cells has a negative eﬀect on the
disease process. The complexity of the mutant SOD1 mouse
model is illustrated by the fact that selective removal of
mutant SOD1 in Schwann cells has a negative eﬀect on
survival[81],whilecontroversyexistsontheroleof(mutant)
SOD1 in muscle cells [82–84].
The mutant SOD1 mouse models were also extensively
used to test new therapeutic strategies. One famous example
is minocycline, a drug that inhibits microglial activation and
thatshowsapositiveeﬀectinthreeindependentstudiesusing
two diﬀerent mutant SOD1 models [85–87]. However, the
subsequent clinical study was negative [88]. Because of this
and many other failures, the validity of the mutant SOD1
models were questioned [89]. However, there could be many
good reasons for the negative human clinical trials. First of
all, the diﬀerences in pharmacokinetics between mice and
humans are often largely neglected. In addition, it could
be that the eﬀects observed in the mouse are small andJournal of Biomedicine and Biotechnology 5
can be missed in a clinically and genetically heterogeneous
human ALS population. One also has to realize that some
positive results in mice were obtained from underpowered
studies in which the treatment is started before disease onset
[89, 90], while human clinical trials are done with patients
already suﬀering from ALS. In order to circumvent these
problems, clear guidelines were formulated outlining the
standard operating procedures (SOPs) for preclinical animal
research[91].Lastbutnotleast,itisalsopossiblethatmutant
SOD1 mice do not model sporadic ALS, but only represent
an animal model of familial ALS or even only of familial ALS
caused by mutations in SOD1 [89].
3.1.2. Transgenic Rats. Transgenic rats overexpressing
mutant (H46R and G93A) SOD1 were also created and
these animals also develop an age-dependent degeneration
of motor neurons leading to paralysis and death [37, 38].
The advantage of this larger rat model is that it allows
studies involving complex manipulations of the spinal ﬂuid
and spinal cord (e.g., implantation of intrathecal catheters
for chronic therapeutic studies, sampling of cerebrospinal
ﬂuid,...). A major diﬀerence between the rat and mouse
mutant SOD1 models is the more rapid progression of
the disease in rats which could be due to respiratory
insuﬃciency resulting from the degeneration of respiratory
motor neurons [92]. In addition, part of the transgenic rats
show weakness in the forelimbs as ﬁrst clinical sign [38], a
phenotype that becomes more pronounced after chronic
stimulation of the phrenic nerve [93].
3.2. ALS6: FUS/TLS; 16p11. Recently, two studies reported
the discovery of mutations in FUS (fused in sarcoma)/TLS
(translocated in liposarcoma) as a new genetic cause of ALS
in Cape Verde, the USA, Australia and the UK [10, 11]. The
FUS/TLS gene is located in a region on chromosome 16
previously associated with ALS6 [94]. FUS/TLS mutations
were also found in other populations in Europe and the US
and it is estimated that FUS/TLS mutations are the cause
of familial ALS in 4%-5% of cases. FUS/TLS linked ALS
is a dominant disease, except in the original Cape Verdean
family in which the FUS mutation is recessive [10]. Although
in-frame deletions and insertions have been reported, most
mutationsaremissense,andthemajorityislocatedinthelast
exon.
The FUS/TLS protein is involved in RNA metabolism
and regulation of transcription. FUS/TLS knockout mice die
immediately after birth [40] or are rarely alive at weaning
[41]( Table 2). In an outbred strain, FUS/TLS knock out
mice survive but show male sterility and reduced fertility of
females [41]. Neurons deﬁcient for FUS/TLS show abnormal
spine morphology and lower spine density [95]. No loss of
motor neurons and/or a motor phenotype were reported
indicating that mutant FUS/TLS induces the disease by
a “gain-of-function” mechanism. Currently, no transgenic
mice and/or rats are available that (over)express mutant
and/or wild type FUS/TLS.
3.3. ALS10: TDP-43; 1p36. Transactivation response DNA-
binding protein with molecular weight 43kD (TDP-43)
was ﬁrst identiﬁed as one of the major constituents of the
intraneuronal inclusions observed in ALS and frontotem-
poral lobar degeneration with ubiquitin-positive inclusions
(FTLD-U) [96]. Subsequently, mutations in the TARDBP
gene encoding TDP-43 were identiﬁed in patients with
familial ALS [5–9]. The mutations found in the TARDBP
gene are missense mutations and are almost exclusively
located in the C-terminal part of the protein [97]. TARDBP
mutations are rare and account for less than 5% of familial
ALS.
TDP-43 has two RNA binding domains and a glycine-
rich domain in the C-terminal part, with which it binds to
various heterogeneous nuclear nucleoproteins (hnRNPs). It
is more abundantly present in the nucleus than in the cyto-
plasm. Although the exact role of TDP-43 is incompletely
understood, it is thought to play a role in RNA processing,
stabilisation, and transport [98, 99].
Transgenic mice were created by overexpression of
mutant (A315T) TDP-43 under the control of the mouse
prion promoter [42]. These transgenic mice are born at
normal Mendelian ratios, have the same weight as non-
transgenic littermates, and appear normal up to 3 months
of age [42]. From that moment on, the transgenic mice
develop gait abnormalities, begin to lose weight, and
develop a “swimming” gait. The life span of the animals
is approximately 5 months. These transgenic animals show
degeneration of motor neurons and of layer 5 pyramidal
neurons in the frontal cortex. The degenerating neurons
contain ubiquitinated aggregates, negative for (mutant)
TDP-43. The authors were not able to create wild-type TDP-
43 overexpressing mice and as a consequence the question
remained whether these ﬁndings are the result of the TDP-43
mutation or of the overexpression of TDP-43.
The latter seems to be the case as overexpression of
human wild-type TDP-43 driven by the Thy-1 promotor
also results in toxicity. These transgenic mice develop gait
abnormalities and show degeneration of motor neurons and
neurons in layer 5 of the frontal cortex [43]. In addition,
nuclear and cytoplasmic aggregates of ubiquitinated and
phosphorylated TDP-43 are clearly present [43]. A number
of recent studies conﬁrm these ﬁndings in transgenic mice
that overexpress wild-type TDP-43 under the control of the
prion promoter [44, 45]( Table 2). Altogether, these data
indicate that it is the overexpression of TDP-43 that is toxic.
In addition to the diﬀerent mouse models, a conditional
rat model was created in which wild-type TDP-43 or mutant
(M337V) TDP-43 is expressed under the control of a
promoter that can be silenced by treating the transgenic
rats with doxycycline [46]( Table 2). While constitutive or
early embryonic expression of the mutant (M337V) TDP-
43 transgene causes embryonic death, postnatal expression
of the transgene induces paralysis and death. The severity
of the phenotype diﬀers between the diﬀerent lines and
relates to the copy number of the transgene. In contrast,
wild-type TDP-43 overexpression does not lead to a disease
phenotype despite the fact that the transgene is expressed
at a comparable level, indicating that the phenotype is
due to mutations in TDP-43 and not to overexpression of
TDP-43 [46]. The mutant (M337V) TDP-43 transgenic rats6 Journal of Biomedicine and Biotechnology
show neuronal degeneration, initially of motor neurons but
in a later disease state also of cortical, hippocampal, and
cerebellar neurons [46]. Also in the rat model, ubiquitinated
TDP-43 inclusions are scarce indicating that this rat model
doesnotreplicateallthepathogenicfeaturesobservedinALS
patients. Most likely, a more sophisticated approach such as
a “knock-out/knock-in” mouse will be necessary to solve this
problem and to obtain a good mutant TDP-43 related rodent
model of ALS.
4. Rodent Models of Atypical or
RareMendelianFALS
4.1. ALS2: Alsin; 2q33. ALS2 is a rare autosomal, recessive
form of ALS that is characterized by a juvenile onset of
progressive spasticity in the limbs, facial, and pharyngeal
muscles. In families of Arabic origin, mutations in the ALS2
gene on chromosome 2 were discovered [12]. At present, at
least 11 diﬀerent mutations in the ALS2 gene were reported
leading either to ALS, or to primary lateral sclerosis (PLS),
or to infantile onset ascending hereditary spastic paraplegia
(IAHSP) with only upper motor neurons involved (for
ar e v i e ws e e[ 1]). All patients are homozygous for the
mutant gene, and all reported mutations lead to premature
termination of the transcript and as a consequence to a
truncated protein.
Several groups generated an alsin knockout mouse [50–
53]( Table 3), but these mice had no clear motor phenotype.
Primary motor neuron cultures from the ﬁrst line of alsin
knockout mice are more susceptible to oxidative stress
[50]. The second transgenic mouse model shows an age-
dependent, slowly progressive loss of cerebellar Purkinje
cells and a disturbance of spinal motor neurons associated
with astrocytosis and microglial cell activation, indicating a
subclinical dysfunction of the motor system [51]. The third
mouse model shows a mild, age-independent hypoactivity
and smaller cortical motor neurons. In addition, distur-
bances in endosomal transport were reported [52]. The
fourth transgenic model shows slowed movement without
muscle weakness and progressive axonal degeneration in the
lateral spinal cord [53]. From all these observations, it can be
concluded that knocking out alsin in mouse is insuﬃcient to
cause major motor deﬁcits, while subtle behavioral changes
and a clear loss in cerebellar Purkinje cells are present.
4.2. ALS8: VAPB; 20q13. A missense mutation in the VAPB
gene was found in a Brazilian family [15], and this mutation
results in diﬀerent clinical manifestations including late-
onset spinal muscular atrophy and late-onset atypical ALS
with slow progression. To date, there are 8 families of
which 7 are of Portuguese-Brazilian and one is of African-
Brazilian origin. Both wild-type and mutant VAPB, were
overexpressed in neurons. Recently, transgenic mice were
created that express either wild-type VAPB or mutant (P56S)
VAPB in the nervous system using a modiﬁed prion pro-
moter [54]. These mice develop no overt motor phenotype
and show no alterations in survival. Interestingly, mutant
(P56S) VAPB overexpressing mice show cytoplasmic TDP-43
accumulations in the motor neurons of the spinal cord [54].
4.3. Dynactin; 2p13. A G59S mutation located in the
microtubule-binding domain of dynactin p150Glued was
described as the cause of an autosomal dominant, late-
onset motor neuron disease in a large family of European
descent [18]. Initial in vitro microtubule binding studies
indicated that mutant p150Glued exhibit a reduced binding
eﬃciency to microtubules [18], which is consistent with
a “loss-of-function.” In addition, cell culture experiments
demonstrated that mutant G59S p150Glued perturbs dyn-
a c t i nf u n c t i o na n dc a u s e sp r o t e i na g g r e g a t i o n[ 100]. More
recently,anumberofmousemodelswerecreatedfromwhich
it can be concluded that motor neuron loss is caused by
a dominant negative mechanism [55, 56]. Lai et al. (2007)
generated a mutant G59S p150Glued knock-in mouse. Early
embryoniclethalityisobservedinthemutantG59Sp150Glued
homozygous knock-in mice, while the heterozygous mutant
G59S p150Glued mice start to display a motor neuron disease-
like phenotype at 10 months of age. This is accompanied by
excessive accumulation of cytoskeletal and synaptic vesicle
proteins at the neuromuscular junctions, loss of spinal
motor neurons, increase of astrogliosis, and shortening of
gait [55]. Laird et al. (2008) and Chevalier-Larsen et al.
(2008) constructed transgenic mice that overexpress mutant
G59S p150Glued under the control of the neuron-speciﬁc
Thy-1 promoter [56, 57]. These mice also display a motor
phenotype resulting in muscle weakness, paralysis, and/or
death (Table 3).
5. Rodent Models Based onCandidateGenes
5.1. Neuroﬁlaments and Peripherin. Neuroﬁlaments (NFs)
are the most abundant intermediate ﬁlaments in neurons
and consist of three subunits: NF-L, NF-M, and NF-H.
NF accumulations are found in both familial and sporadic
ALS cases [101, 102]. In a limited number of ALS patients,
mutations in the KSP phosphorylation domain seem to be
present [103]. Over the years, a large number of transgenic
mice with modiﬁcations related to NFs were made in
an attempt to determine the role of these intermediate
ﬁlamentsinthepathologyofmotorneurons(forareviewsee
[104]).
Knockout mice for these diﬀerent subunits alone or
double transgenic mice deﬁcient in two NF subunits do not
show a clear phenotype, although some of these mice show
a loss of motor axons. Also overexpression of the diﬀerent
NF subunits does not induce motor neuron death. In some
of these transgenic mice NF accumulations in neuronal cell
bodies were found, but this does not induce motor neuron
death. However, NF abnormalities can induce selective
motor neuron death in vivo as indicated by a transgenic
mouse expressing a mutant NF-L. In these mice, leucine at
position 394 was mutated into a proline, and this causes
a dominant motor neuron disease [58]. These transgenic
mice show massive, selective degeneration of motor neurons
accompaniedbyaccumulationsofNFs,althoughnoeﬀecton
the life span of these mice was reported. This mouse model
is very interesting and relevant as NF-L mutations are the
cause of a dominantly inherited motor neuropathy: Charcot-
Marie-Tooth disease, type 2E [105].Journal of Biomedicine and Biotechnology 7
More recently and because of the proposed role of
RNA metabolism in the pathogenesis of ALS, a transgenic
mouse overexpressing the 3- U T Ro fN F - Lr e c e i v e dr e n e w e d
interest [106]. This transgenic mouse presents with neuronal
aggregates, astrocytosis, and impaired motor function [107].
As the endogenous level of NF-L protein is normal, it is
suggested that sequences in the 3-UTR of NF-L bind trans-
acting factors that are essential for a normal motor neuron
function [106].
A frameshift deletion and a mutation in the peripherin
gene encoding another intermediate ﬁlament protein were
discovered in ALS patients [108, 109]. Peripherin is mostly
expressed in the peripheral nervous system and is upreg-
ulated both in the peripheral and central nervous system
after injury and by inﬂammatory cytokines. Transgenic
mice that overexpress wild-type peripherin develop motor
dysfunctions very late in their life (after 2 years). This
phenotype is accompanied by the loss of motor axons and by
the appearance of peripherin inclusion bodies in the motor
neurons. The onset of motor dysfunction and axonal loss is
dramatically accelerated by the absence of NF-L, as revealed
bycrossbreedingofperipherin overexpressingmicewithNF-
L knockout mice. These double transgenic mice also show a
dramatic loss of motor neurons [59].
5.2. Growth Factors. Survival of motor neurons is depen-
dent on the presence of growth factors. Absence of these
neurotrophic factors can cause motor neuron death, as is
illustrated by the phenotype of the transgenic mice in which
the gene for ciliary neurotrophic factor (CNTF) is deleted
[110]. CNTF is a cytosolic protein, expressed at high levels
in myelinating Schwann cells, promoting survival of motor
neurons in vitro. These knockout mice have no phenotype
during the postnatal weeks, but develop atrophy and loss of
motor neurons with aging [110].
Another example of motor neuron death induced by
insuﬃc i e n tg r o w t hf a c t o r si st h eV E G F δ/δ transgenic mouse.
This mouse model was created by deleting the hypoxia-
response element (HRE) in the promoter region of the gene
encoding VEGF. This modiﬁcation induces an adult-onset,
slowly progressive motor neuron loss leading to muscle
atrophy and a motor phenotype [60]. Despite the fact that
the VEGFδ/δ mice show clear motor neuron loss and muscle
atrophy, these animals do not become paralyzed and have a
normal life span.
5.3. Tau. Manipulations involving the gene encoding the
microtubule-associated protein, tau, also resulted in a num-
ber of mouse models showing a clear motor phenotype. Tau
is an axonal phosphoprotein that establishes short cross-
bridges between axonal microtubules and, thereby, supports
intracellular traﬃcking, including axonal transport. In neu-
rons aﬀected by a tauopathy, tau is hyperphosphorylated
and is located not only in axons but also in cell bodies and
dendrites. Tau is the major component of the intracellular
ﬁlamentous deposits found in a number of neurodegenera-
tive diseases including Alzheimer’s disease, while mutations
in tau are associated with frontotemporal dementia with
parkinsonism (FTDP) (for a review see [111]). Several tau
transgenic mice show a progressive motor phenotype with
muscle atrophy. Overexpression of mutant tau also induces
age-dependent accumulation of insoluble ﬁlamentous tau
aggregates in neuronal perikarya of spinal cord, a motor
phenotype anda reducedlife span [61–67](Table 3).Despite
these motor phenotypes, evidence is lacking that tau plays a
role in the pathogenesis of ALS [112].
6. Conclusions
For more than a decade, the mutant SOD1 mice and rats
havebeentheprototypeofanidealmodeltostudy(selective)
motor neuron death, the hallmark of ALS. However, the
major frustration is that this almost perfect model did not
lead to a major breakthrough on the therapeutic level. All
positive therapeutic interventions in this model failed in
subsequent human clinical trials. As a consequence, the
ALS ﬁeld is eagerly awaiting new rodent models that are
generated starting from other mutated genes. Until recently,
these attempts were based on genetic defects causing atypical
or very rare forms of familial ALS. Since the discovery of
mutationsinthegenesencodingTDP-43andFUS/TLS,hope
arises that (over) expression of these mutated genes will lead
tothegenerationofnewALSmodels.Despitealargenumber
of attempts, the rodent models based on (mutant) TDP-43
are not yet perfect. These models lack speciﬁcity in relation
to the mutation and/or the cell type aﬀected. The value of
the rodent models that are the result of modiﬁcation of
genes that unexpectedly cause a motor neuron phenotype
is unclear. In the best case, these models point to a new
pathogenic mechanism. None of these models is currently
used for routine drug screening.
In conclusion, the mutant SOD1 rodent models remains
the best models currently available to study the pathogenesis
of ALS and to test new therapies, although the question
remainshowrepresentativethismodelisforhumansporadic
and familial ALS. As a consequence, searching for more
and better rodent models based on mutations in new genes
remains an important challenge in the ALS ﬁeld.
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